Epigral is betting big on expanding into epoxy resins and other new chemicals, but the payoff may take longer than investors expect if demand, pricing, or customer approvals don’t ramp smoothly. With more spending and borrowing underway, the company’s next phase could bring bigger swings in results before the longer-term benefits show up.Read more
Epigral is betting that bigger plants, tighter control of key inputs, and a push into higher-value specialty chemicals can turn it into a more reliable exporter as global buyers look beyond China. The catch is that this growth plan needs heavy spending and smooth project ramp-ups, and tougher rules or new big competitors could squeeze profits.Read more
Epigral is betting big on new specialty chemical plants and using more of its own chlorine instead of selling it, which could make its business steadier and more profitable over time. The key question is whether these expansions ramp smoothly and customer demand holds up, or whether energy and supply shocks derail the plan.Read more
No trending discussion available.
Epigral Limited manufactures and sells chlor-alkali and derivative products in India and internationally. The company offers chlorinated polyvinyl chloride (CPVC) resin, epichlorohydrin, chloromethanes value chain, hydrogen peroxide, caustic soda and potash, chlorine, hydrogen, chloromethanes, captive power plant (CPP), and chlorotoluene value chain, as well as operates wind-solar hybrid power plant. Its products are used in CPVC pipes and fittings, windmills, construction, paints and coatings, electronics, water treatment, agrochemicals, pharmaceuticals, refineries, soap and detergents, fluoropolymers, paper and pulp, textiles, alumina, polyurethane foam, lithium, and polytetrafluoroethylene (PTFE) pipes. The company was formerly known as Meghmani Finechem Limited and changed its name to Epigral Limited in August 2023. Epigral Limited was incorporated in 2007 and is based in Ahmedabad, India.
